This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
Read original at benzingaStocks · News reference
Bausch Health And Solta Medical Announce Thermage Awarded AAA Well-Known Trademark Certification By China Trademark Association
Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- May 28, 2026, 8:43 PM
- Checked
- May 28, 2026, 8:43 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Bausch Health Companies stock surged nearly 40% in July 2026, driven by a regulatory win in Canada for its Prokedi schizophrenia drug and a strong Q2 earnings beat. The company reported $2.85 billion in revenue (13% YoY growth) and adjusted net income of $476 million ($1.26 per share), exceeding analyst expectations. Management raised full-year 2026 guidance for both revenue and adjusted EBITDA, citing strength across its diversified pharmaceutical portfolio.
Read original at the-motley-foolBausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est
Read original at benzinga8-K filing — Bausch Health Companies Inc. (BHC)
Filed: 2026-07-29 AccNo: 0000885590-26-000105 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarBausch Health Companies Q2 Adj. EPS $1.26 Beats $1.06 Estimate, Sales $2.852B Beat $2.679B Estimate
Read original at benzingaBausch Health, Canada, Completes Negotiations With pan-Canadian Pharmaceutical Alliance Resulting In LOI For PrOKEDI 75mg And 100mg, Long-Acting Injectable Antipsychotic Agent For Schizophrenia Treatment
Read original at benzinga